<DOC>
	<DOCNO>NCT01662466</DOCNO>
	<brief_summary>The purpose study determine effect treatment trans-dermal testosterone cream compare placebo measure ovarian reserve , oocyte embryo quality , pregnancy rate among woman evidence diminish ovarian reserve persistently low serum testosterone free testosterone complete six previous week DHEA supplementation .</brief_summary>
	<brief_title>Effect Testosterone Treatment Embryo Quality</brief_title>
	<detailed_description>At CHR investigator use DHEA supplementation improve ovarian response ovulation induction vitro fertilization five year ( Barad , Brill et al . 2007 ; Barad , Weghofer et al .2009 ; Gleicher , Ryan et al . 2009 ; Gleicher , Weghofer et al . 2010 ; Gleicher Barad 2011 ) . Our view effect androgens follicular environment recently review ( Gleicher , Weghofer et al . 2011 ) . A recent analysis androgen metabolite DHEA patient suggest woman successfully respond DHEA supplementation increase egg production clinical pregnancy testosterone normal median value reproductive age woman . There also appear cohort woman respond DHEA low serum testosterone . The investigator decide investigate supplementing woman testosterone normal female range would improve ovarian function possibly increase pregnancy rate . Recruitment &amp; Experimental Plan - A baseline blood draw follow completion 6 week DHEA supplementation determine eligibility study . The baseline blood determination part standard pre cycle screen CHR patient . - After sign informed consent subject randomly assign either active testosterone cream treatment placebo . - Active treatment consist testosterone delivery system deliver transdermal testosterone cream ( 0.5 mg per gram cream . ) The cream placebo cream compound Metro Drugs ( New York , NY ) dispense calibrate pump deliver one gram cream per stroke . Transdermal absorption 10 % 2 gram ( 1.0 mg ) per day apply skin deliver 100 ug per day . In preliminary analysis determine 2 gram dose preparation raise total testosterone target range 50 100 ng/dL . - The dose testosterone cream 2 gram cream per day apply leave inner forearm . The study medication continue apply 6 week . - All patient evidence diminish ovarian reserve practice treat DHEA . Thus , patient study receive DHEA + testosterone DHEA + Placebo . Patients achieve level serum testosterone desire range use DHEA alone eligible study .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Infertility , Female</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Women 38 44 year old planning undergo ovulation induction IVF willing sign inform consent . BMI &gt; 18 &lt; = 30 kg/m^2 FSH &gt; 10 mIU/mL AMH = &lt; 1.05 ng/mL Using DHEA treatment DOR/POA . Baseline Total Testosterone less 30 ng per deciliter ( 1.0 nmol per liter ) serum free testosterone concentration less 3.5 pg per milliliter ( 12.1 pmol per liter ) , median value normal premenopausal woman ( Endocrine Sciences , Calabasas Hills , Calif. ) . History hormone dependent neoplasm History severe acne hirsutism . Hyperlipidemia . Pre exist cardiac , renal hepatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>38 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>testosterone</keyword>
	<keyword>DHEA</keyword>
	<keyword>IVF</keyword>
	<keyword>egg quality</keyword>
	<keyword>pregnancy rate</keyword>
</DOC>